IRON vs. SVRA, AUPH, PRTC, COGT, ARCT, SIGA, WVE, DNTH, MLYS, and YMAB
Should you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Savara (SVRA), Aurinia Pharmaceuticals (AUPH), PureTech Health (PRTC), Cogent Biosciences (COGT), Arcturus Therapeutics (ARCT), SIGA Technologies (SIGA), Wave Life Sciences (WVE), Dianthus Therapeutics (DNTH), Mineralys Therapeutics (MLYS), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
Disc Medicine (NASDAQ:IRON) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Savara received 261 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 73.53% of users gave Disc Medicine an outperform vote while only 65.90% of users gave Savara an outperform vote.
Disc Medicine's return on equity of -22.81% beat Savara's return on equity.
Disc Medicine has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 4.2% of Disc Medicine shares are held by company insiders. Comparatively, 4.6% of Savara shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Disc Medicine had 4 more articles in the media than Savara. MarketBeat recorded 18 mentions for Disc Medicine and 14 mentions for Savara. Disc Medicine's average media sentiment score of 0.23 beat Savara's score of 0.17 indicating that Disc Medicine is being referred to more favorably in the media.
Savara is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.
Disc Medicine currently has a consensus price target of $57.71, indicating a potential upside of 82.76%. Savara has a consensus price target of $8.20, indicating a potential upside of 73.00%. Given Disc Medicine's higher possible upside, equities analysts plainly believe Disc Medicine is more favorable than Savara.
Summary
Disc Medicine beats Savara on 8 of the 15 factors compared between the two stocks.
Get Disc Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Disc Medicine Competitors List
Related Companies and Tools
